Abstract
We examine whether U.S. states can use their market power to reduce the costs of supplying prescription drugs to uninsured and underinsured persons with HIV through a public program, the AIDS Drug Assistance Program (ADAP). Among states that purchase drugs from manufacturers and distribute them directly to clients, those that purchase a greater volume pay lower average costs per prescription. Among states depending on retail pharmacies to distribute drugs and then claiming rebates from manufacturers, those that contract with smaller numbers of pharmacy networks have lower average costs. Average costs per prescription do not differ between the two purchase methods.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Berndt E.R. (2002). Pharmaceuticals in U.S. health care: Determinants of quantity and price. The Journal of Economic Perspectives 16: 45–66
Berwick D. (2002). We all have AIDS: Case for reducing the cost of HIV drugs to zero. British Medical Journal 324: 214–218
California State Office of AIDS. (2004). unpublished report on state expenditures by drug class.
Centers for Disease Control and Prevention (CDC). (2005). HIV/AIDS Surveillance Report 2005 (Vol. 17). Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Accessed March 8, 2007 at: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2005report/default.htm.
Clinton Foundation. (2006). Agreements with Nine Companies Will Lower Prices of HIV Diagnosis and Two HIV/AIDS Medicines by 30–50 Percent for 50 Countries. Clinton Foundation Press Release dated January 12, 2006. New York, NY: Clinton Foundation. Available at www.clintonfoundation.org/011206-nr-cf-hs-ai-isr-ind-chn-zaf. Accessed 24 March 2006.
Davis, M. D., Aldridge, C., Kates, J., & Chou, L. (2003). National ADAP Monitoring Project. Annual Report. Washington, D.C.: The Kaiser Family Foundation and National Alliance of State and Territorial AIDS Directors.
DHHS. Office of Inspector General. (2001). Cost Containment of Medicaid HIV/AIDS Drug Expenditures. Washington, D.C.: DHHS Office of Evaluation and Inspections. OEI-05-99-00611.
Frank R.G. (2001). Prescription drug prices: Why do some pay more than others do?. Health Affairs 20: 115–28
Grinberg L. (1998). Soaring prices, soaring sales. GMHC Treatment Issues 12(12): 5–7
Kates, J., Penner, M., Crutsinger-Perry, B., Leggoe, AW. Singleton, N. (2005). National ADAP Monitoring Project. Annual Report 2005. Washington, D.C.: The Kaiser Family Foundation and National Alliance of State and Territorial AIDS Directors.
Kates, J., Penner, M. Crutsinger-Perry, B. Carbaugh, A. L. Singleton, N. (2006). National ADAP Monitoring Project. Annual Report 2006. Washington, D.C.: The Kaiser Family Foundation and National Alliance of State and Territorial AIDS Directors. Available at: www.kff.org/hivaids/upload/7464.pdf. Accessed March 30, 2006.
Richardson, K. (n.d.). The Public Health Service (PHS) Section 340B Drug Pricing Program In Basic Language. (Draft). Accessed 3/8/07 at http://pssc.aphanet.org/pdfs/340b_handbook.pdf
Scherer F.M. (2000). The Pharmaceutical Industry. In Culyer A.J., Newhouse J.P. (eds). Handbook of health economics (Vol. 1). Amsterdam, Elsevier Science, pp. 1297-1336
U.S. Government Accountability Office. (1998). HIV/AIDS Drugs: Funding Implications of New Combination Therapies for Federal and State Programs. Washington, D.C.: GAO/HEHS-99-2.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Leibowitz, A.A., Sood, N. Market power and state costs of HIV/AIDS drugs. Int J Health Care Finance Econ 7, 59–71 (2007). https://doi.org/10.1007/s10754-007-9012-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10754-007-9012-0